{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T01:07:34Z","timestamp":1773623254819,"version":"3.50.1"},"reference-count":128,"publisher":"Pleiades Publishing Ltd","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochemistry Moscow"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1134\/s0006297924604441","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:22:00Z","timestamp":1751372520000},"page":"650-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of m6A-RNA Methylation in the Development, Progression, and Treatment Response of Bladder Cancer"],"prefix":"10.1134","volume":"90","author":[{"given":"Tatiana","family":"Sinyagovskaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliya","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalya","family":"Vinchevskaya-Khmelnitskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisha","family":"Agabalaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Ponomareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Brezgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Goptar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Chulanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alim","family":"Dymov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Vinarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Kostyushev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasiya","family":"Kostyusheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2864_CR1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024) Global cancer observatory: cancer today, Int. Agency Res., URL: https:\/\/gco.iarc.who.int\/today."},{"key":"2864_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M. Burger","year":"2013","unstructured":"Burger, M., Catto, J. W. F., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeney, L. A., La Vecchia, C., Shariat, S., and Lotan, Y. (2013) Epidemiology and risk factors of urothelial bladder cancer, Eur. Urol., 63, 234-241, \nhttps:\/\/doi.org\/10.1016\/j.eururo.2012.07.033.","journal-title":"Eur. Urol."},{"key":"2864_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5489\/cuaj.777","volume":"4","author":"S. Aldousari","year":"2010","unstructured":"Aldousari, S., and Kassouf, W. (2010) Update on the management of non-muscle invasive bladder cancer, Can. Urol. Assoc.\u00a0J., 4, 56-64, \nhttps:\/\/doi.org\/10.5489\/cuaj.777.","journal-title":"Can. Urol. Assoc.\u00a0J."},{"key":"2864_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205019","volume":"14","author":"A. T. Shalata","year":"2022","unstructured":"Shalata, A. T., Shehata, M., Van Bogaert, E., Ali, K. M., Alksas, A., Mahmoud, A., El-Gendy, E. M., Mohamed, M. A., Giridharan, G. A., Contractor, S., and El-Baz, A. (2022) Predicting recurrence of non-muscle-invasive bladder cancer: current techniques and future trends, Cancers, 14, 5019, \nhttps:\/\/doi.org\/10.3390\/cancers14205019.","journal-title":"Cancers"},{"key":"2864_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09733-8","volume":"22","author":"S. Jeong","year":"2022","unstructured":"Jeong, S., Han, J. H., Jeong, C. W., Kim, H. H., Kwak, C., Yuk, H. D., and Ku, J. H. (2022) Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor, BMC Cancer, 22, 631, \nhttps:\/\/doi.org\/10.1186\/s12885-022-09733-8.","journal-title":"BMC Cancer"},{"key":"2864_CR6","doi-asserted-by":"publisher","first-page":"239.e1","DOI":"10.1016\/j.urolonc.2018.01.018","volume":"36","author":"D. D\u2032Andrea","year":"2018","unstructured":"D\u2032Andrea, D., Abufaraj, M., Susani, M., Ristl, R., Foerster, B., Kimura, S., Mari, A., Soria, F., Briganti, A., Karakiewicz, P. I., Gust, K. M., Roupr\u00eat, M., and Shariat, S. F. (2018) Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool, Urol. Oncol., 36, 239.e1-239.e7, \nhttps:\/\/doi.org\/10.1016\/j.urolonc.2018.01.018.","journal-title":"Urol. Oncol."},{"key":"2864_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1261\/rna.072785.119","volume":"26","author":"D. A. Lorenz","year":"2020","unstructured":"Lorenz, D. A., Sathe, S., Einstein, J. M., and Yeo, G. W. (2020) Direct RNA sequencing enables m(6)A detection in endogenous transcript isoforms at base-specific resolution, RNA, 26, 19-28, \nhttps:\/\/doi.org\/10.1261\/rna.072785.119.","journal-title":"RNA"},{"key":"2864_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102694","volume":"10","author":"L. Shu","year":"2021","unstructured":"Shu, L., Huang, X., Cheng, X., and Li, X. (2021) Emerging roles of N6-methyladenosine modification in neurodevelopment and neurodegeneration, Cells, 10, 2694, \nhttps:\/\/doi.org\/10.3390\/cells10102694.","journal-title":"Cells"},{"key":"2864_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.656849","volume":"9","author":"G. Sokpor","year":"2021","unstructured":"Sokpor, G., Xie, Y., Nguyen, H. P., and Tuoc, T. (2021) Emerging role of m(6)A methylome in brain development: implications for neurological disorders and potential treatment, Front. Cell Dev. Biol., 9, 656849, \nhttps:\/\/doi.org\/10.3389\/fcell.2021.656849.","journal-title":"Front. Cell Dev. Biol."},{"key":"2864_CR10","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3892\/ijmm.2020.4746","volume":"46","author":"Y. Qin","year":"2020","unstructured":"Qin, Y., Li, L., Luo, E., Hou, J., Yan, G., Wang, D., Qiao, Y., and Tang, C. (2020) Role of m6A RNA methylation in cardiovascular disease (review), Int. J. Mol. Med., 46, 1958-1972, \nhttps:\/\/doi.org\/10.3892\/ijmm.2020.4746.","journal-title":"Int. J. Mol. Med."},{"key":"2864_CR11","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/cvr\/cvab160","volume":"118","author":"R. Kumari","year":"2022","unstructured":"Kumari, R., Ranjan, P., Suleiman, Z. G., Goswami, S. K., Li, J., Prasad, R., and Verma, S. K. (2022) mRNA modifications in cardiovascular biology and disease: with a focus on m6A modification, Cardiovasc. Res., 118, 1680-1692, \nhttps:\/\/doi.org\/10.1093\/cvr\/cvab160.","journal-title":"Cardiovasc. Res."},{"key":"2864_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-virology-092818-015559","volume":"6","author":"G. D. Williams","year":"2019","unstructured":"Williams, G. D., Gokhale, N. S., and Horner, S. M. (2019) Regulation of viral infection by the RNA modification N6-methyladenosine, Annu. Rev. Virol., 6, 235-253, \nhttps:\/\/doi.org\/10.1146\/annurev-virology-092818-015559.","journal-title":"Annu. Rev. Virol."},{"key":"2864_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.gpb.2020.06.003","volume":"18","author":"Y. Li","year":"2020","unstructured":"Li, Y., Zhang, Q., Cui, G., Zhao, F., Tian, X., Sun, B.-F., Yang, Y., and Li, W. (2020) m(6)A regulates liver metabolic disorders and hepatogenous diabetes, Genom. Proteom. Bioinform., 18, 371-383, \nhttps:\/\/doi.org\/10.1016\/j.gpb.2020.06.003.","journal-title":"Genom. Proteom. Bioinform."},{"key":"2864_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00922","volume":"10","author":"C. Zhang","year":"2019","unstructured":"Zhang, C., Fu, J., and Zhou, Y. (2019) A review in research progress concerning m6A Methylation and Immunoregulation, Front. Immunol., 10, 922, \nhttps:\/\/doi.org\/10.3389\/fimmu.2019.00922.","journal-title":"Front. Immunol."},{"key":"2864_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01952-4","volume":"40","author":"F. Tan","year":"2021","unstructured":"Tan, F., Zhao, M., Xiong, F., Wang, Y., Zhang, S., Gong, Z., Li, X., He, Y., Shi, L., Wang, F., Xiang, B., Zhou, M., Li, X., Li, Y., Li, G., Zeng, Z., Xiong, W., and Guo, C. (2021) N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies, J.\u00a0Exp. Clin. Cancer Res., 40, 146, \nhttps:\/\/doi.org\/10.1186\/s13046-021-01952-4.","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"2864_CR16","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.3892\/ol.2018.9395","volume":"16","author":"K. Hong","year":"2018","unstructured":"Hong, K. (2018) Emerging function of N6-methyladenosine in cancer, Oncol. Lett., 16, 5519-5524, \nhttps:\/\/doi.org\/10.3892\/ol.2018.9395.","journal-title":"Oncol. Lett."},{"key":"2864_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.euo.2018.08.018","volume":"2","author":"A. B. Weiner","year":"2019","unstructured":"Weiner, A. B., Desai, A. S., and Meeks, J. J. (2019) Tumor location may predict adverse pathology and survival following definitive treatment for bladder cancer: a national cohort study, Eur. Urol. Oncol., 2, 304-310, \nhttps:\/\/doi.org\/10.1016\/j.euo.2018.08.018.","journal-title":"Eur. Urol. Oncol."},{"key":"2864_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.juro.2008.03.037","volume":"180","author":"W. Kassouf","year":"2008","unstructured":"Kassouf, W., Spiess, P. E., Brown, G. A., Liu, P., Grossman, H. B., Dinney, C. P. N., and Kamat, A. M. (2008) Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction, J.\u00a0Urol., 180, 164-167, \nhttps:\/\/doi.org\/10.1016\/j.juro.2008.03.037.","journal-title":"J.\u00a0Urol."},{"key":"2864_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P. Gontero","year":"2024","unstructured":"Gontero, P., Birtle, A., Capoun, O., Comp\u00e9rat, E., Dominguez-Escrig, J. L., Liedberg, F., Mariappan, P., Masson-Lecomte, A., Mostafid, H. A., Pradere, B., Rai, B. P., van Rhijn, B. W. G., Seisen, T., Shariat, S. F., Soria, F., Soukup, V., Wood, R., and Xylinas, E. N. (2024) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2013 a summary of the 2024 guidelines update, Eur. Urol., 86, 531-549, \nhttps:\/\/doi.org\/10.1016\/j.eururo.2024.07.027.","journal-title":"Eur. Urol."},{"key":"2864_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814374","volume":"24","author":"G. V. Flores Monar","year":"2023","unstructured":"Flores Monar, G. V., Reynolds, T., Gordon, M., Moon, D., and Moon, C. (2023) Molecular markers for bladder cancer screening: an insight into bladder cancer and FDA-approved biomarkers, Int. J. Mol. Sci., 24, 14374, \nhttps:\/\/doi.org\/10.3390\/ijms241814374.","journal-title":"Int. J. Mol. Sci."},{"key":"2864_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116312","volume":"173","author":"J. Fan","year":"2024","unstructured":"Fan, J., Chen, B., Luo, Q., Li, J., Huang, Y., Zhu, M., Chen, Z., Li, J., Wang, J., Liu, L., Wei, Q., and Cao, D. (2024) Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer, Biomed. Pharmacother., 173, 116312, \nhttps:\/\/doi.org\/10.1016\/j.biopha.2024.116312.","journal-title":"Biomed. Pharmacother."},{"key":"2864_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133181","volume":"14","author":"X. Hu","year":"2022","unstructured":"Hu, X., Li, G., and Wu, S. (2022) Advances in diagnosis and therapy for bladder cancer, Cancers (Basel), 14, 3181, \nhttps:\/\/doi.org\/10.3390\/cancers14133181.","journal-title":"Cancers (Basel)"},{"key":"2864_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10010039","volume":"10","author":"R. Batista","year":"2020","unstructured":"Batista, R., Vinagre, N., Meireles, S., Vinagre, J., Prazeres, H., Le\u00e3o, R., M\u00e1ximo, V., and Soares, P. (2020) Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review, Diagnostics, 10, 39, \nhttps:\/\/doi.org\/10.3390\/diagnostics10010039.","journal-title":"Diagnostics"},{"key":"2864_CR24","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","volume":"36","author":"F. Soria","year":"2018","unstructured":"Soria, F., Droller, M. J., Lotan, Y., Gontero, P., D\u2019Andrea, D., Gust, K. M., Roupr\u00eat, M., Babjuk, M., Palou, J., and Shariat, S. F. (2018) An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer, World J. Urol., 36, 1981-1995, \nhttps:\/\/doi.org\/10.1007\/s00345-018-2380-x.","journal-title":"World J. Urol."},{"key":"2864_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"R. J. Sylvester","year":"2016","unstructured":"Sylvester, R. J., Oosterlinck, W., Holmang, S., Sydes, M. R., Birtle, A., Gudjonsson, S., De Nunzio, C., Okamura, K., Kaasinen, E., Solsona, E., Ali-El-Dein, B., Tatar, C. A., Inman, B. A., N\u2019Dow, J., Oddens, J. R., and Babjuk, M. (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma, Eur. Urol., 69, 231-244, \nhttps:\/\/doi.org\/10.1016\/j.eururo.2015.05.050.","journal-title":"Eur. Urol."},{"key":"2864_CR26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/curroncol31020079","volume":"31","author":"S. Lidagoster","year":"2024","unstructured":"Lidagoster, S., Ben-David, R., De Leon, B., and Sfakianos, J. P. (2024) BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer, Curr. Oncol., 31, 1063-1078, \nhttps:\/\/doi.org\/10.3390\/curroncol31020079.","journal-title":"Curr. Oncol."},{"key":"2864_CR27","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1093\/nar\/gkab378","volume":"49","author":"S. Oerum","year":"2021","unstructured":"Oerum, S., Meynier, V., Catala, M., and Tisn\u00e9, C. (2021) A comprehensive review of m6A\/m6Am RNA methyltransferase structures, Nucleic Acids Res., 49, 7239-7255, \nhttps:\/\/doi.org\/10.1093\/nar\/gkab378.","journal-title":"Nucleic Acids Res."},{"key":"2864_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01204-7","volume":"19","author":"T. Wang","year":"2020","unstructured":"Wang, T., Kong, S., Tao, M., and Ju, S. (2020) The potential role of RNA N6-methyladenosine in Cancer progression, Mol. Cancer, 19, 88, \nhttps:\/\/doi.org\/10.1186\/s12943-020-01204-7.","journal-title":"Mol. Cancer"},{"key":"2864_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01224-4","volume":"15","author":"J. Qu","year":"2022","unstructured":"Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., and Cai, Z. (2022) RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential, J.\u00a0Hematol. Oncol., 15, 8, \nhttps:\/\/doi.org\/10.1186\/s13045-022-01224-4.","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"2864_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073800","volume":"23","author":"S. K. Azzam","year":"2022","unstructured":"Azzam, S. K., Alsafar, H., and Sajini, A. A. (2022) FTO m6A demethylase in obesity and cancer: implications and underlying molecular mechanisms, Int. J. Mol. Sci., 23, 3800, \nhttps:\/\/doi.org\/10.3390\/ijms23073800.","journal-title":"Int. J. Mol. Sci."},{"key":"2864_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X. Wang","year":"2014","unstructured":"Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., Ren, B., Pan, T., and He, C. (2014) N6-methyladenosine-dependent regulation of messenger RNA stability, Nature, 505, 117-120, \nhttps:\/\/doi.org\/10.1038\/nature12730.","journal-title":"Nature"},{"key":"2864_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nature14234","volume":"518","author":"N. Liu","year":"2015","unstructured":"Liu, N., Dai, Q., Zheng, G., He, C., Parisien, M., and Pan, T. (2015) N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions, Nature, 518, 560-564, \nhttps:\/\/doi.org\/10.1038\/nature14234.","journal-title":"Nature"},{"key":"2864_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H. Huang","year":"2018","unstructured":"Huang, H., Weng, H., Sun, W., Qin, X., Shi, H., Wu, H., Zhao, B. S., Mesquita, A., Liu, C., Yuan, C. L., Hu, Y.-C., H\u00fcttelmaier, S., Skibbe, J. R., Su, R., Deng, X., Dong, L., Sun, M., Li, C., Nachtergaele, S., Wang, Y., Hu, C., Ferchen, K., Greis, K. D., Jiang, X., Wei, M., Qu, L., Guan, J.-L., He, C., Yang, J., and Chen, J. (2018) Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation, Nat. Cell Biol., 20, 285-295, \nhttps:\/\/doi.org\/10.1038\/s41556-018-0045-z.","journal-title":"Nat. Cell Biol."},{"key":"2864_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-018-0538-8","volume":"561","author":"J. Choe","year":"2018","unstructured":"Choe, J., Lin, S., Zhang, W., Liu, Q., Wang, L., Ramirez-Moya, J., Du, P., Kim, W., Tang, S., Sliz, P., Santisteban, P., George, R. E., Richards, W. G., Wong, K.-K., Locker, N., Slack, F. J., and Gregory, R. I. (2018) mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis, Nature, 561, 556-560, \nhttps:\/\/doi.org\/10.1038\/s41586-018-0538-8.","journal-title":"Nature"},{"key":"2864_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01356-0","volume":"20","author":"M. B. Uddin","year":"2021","unstructured":"Uddin, M. B., Wang, Z., and Yang, C. (2021) The m(6)A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis, Mol. Cancer, 20, 61, \nhttps:\/\/doi.org\/10.1186\/s12943-021-01356-0.","journal-title":"Mol. Cancer"},{"key":"2864_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-018-0034-6","volume":"28","author":"X. Deng","year":"2018","unstructured":"Deng, X., Su, R., Weng, H., Huang, H., Li, Z., and Chen, J. (2018) RNA N(6)-methyladenosine modification in cancers: current status and perspectives, Cell Res., 28, 507-517, \nhttps:\/\/doi.org\/10.1038\/s41422-018-0034-6.","journal-title":"Cell Res."},{"key":"2864_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0847-4","volume":"17","author":"S. Wang","year":"2018","unstructured":"Wang, S., Chai, P., Jia, R., and Jia, R. (2018) Novel insights on m(6)A RNA methylation in tumorigenesis: a double-edged sword, Mol. Cancer, 17, 101, \nhttps:\/\/doi.org\/10.1186\/s12943-018-0847-4.","journal-title":"Mol. Cancer"},{"key":"2864_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.825109","volume":"12","author":"Q. Liu","year":"2021","unstructured":"Liu, Q. (2021) Current advances in N6-methyladenosine methylation modification during bladder cancer, Front. Genet., 12, 825109, \nhttps:\/\/doi.org\/10.3389\/fgene.2021.825109.","journal-title":"Front. Genet."},{"key":"2864_CR39","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20192892","volume":"39","author":"M. Chen","year":"2019","unstructured":"Chen, M., Nie, Z., Wen, X., Gao, Y., Cao, H., and Zhang, S. (2019) m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer, Biosci. Rep., 39, BSR20192892, \nhttps:\/\/doi.org\/10.1042\/BSR20192892.","journal-title":"Biosci. Rep."},{"key":"2864_CR40","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-5993","volume":"10","author":"J. Wu","year":"2022","unstructured":"Wu, J., Wang, X., Xu, H., Tian, J., Ji, H., Zhu, J., Guo, H., and Chen, Z. (2022) Bioinformatics analysis of the correlation between m6A RNA methylation regulators and the immune infiltration and prognosis of bladder cancer, Ann. Transl. Med., 10, 1386, \nhttps:\/\/doi.org\/10.21037\/atm-22-5993.","journal-title":"Ann. Transl. Med."},{"key":"2864_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4312629","volume":"2020","author":"C. Shen","year":"2020","unstructured":"Shen, C., Liu, J., Wang, J., Yang, X., Niu, H., and Wang, Y. (2020) The analysis of PTPN6 for bladder cancer: an exploratory study based on TCGA, Dis. Markers, 2020, 4312629, \nhttps:\/\/doi.org\/10.1155\/2020\/4312629.","journal-title":"Dis. Markers"},{"key":"2864_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34031","volume":"10","author":"N. Wu","year":"2024","unstructured":"Wu, N., Sun, Y., Xue, D., and He, X. (2024) FTO promotes the progression of bladder cancer via demethylating m6A modifications in PTPN6 mRNA, Heliyon, 10, e34031, \nhttps:\/\/doi.org\/10.1016\/j.heliyon.2024.e34031.","journal-title":"Heliyon"},{"key":"2864_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.310","volume":"11","author":"L. Tao","year":"2021","unstructured":"Tao, L., Mu, X., Chen, H., Jin, D., Zhang, R., Zhao, Y., Fan, J., Cao, M., and Zhou, Z. (2021) FTO modifies the m6A level of MALAT and promotes bladder cancer progression, Clin. Transl. Med., 11, e310, \nhttps:\/\/doi.org\/10.1002\/ctm2.310.","journal-title":"Clin. Transl. Med."},{"key":"2864_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00762-z","volume":"7","author":"G. Zhou","year":"2021","unstructured":"Zhou, G., Yan, K., Liu, J., Gao, L., Jiang, X., and Fan, Y. (2021) FTO promotes tumour proliferation in bladder cancer via the FTO\/miR-576\/CDK6 axis in an m6A-dependent manner, Cell Death Discov., 7, 329, \nhttps:\/\/doi.org\/10.1038\/s41420-021-00762-z.","journal-title":"Cell Death Discov."},{"key":"2864_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10353-5","volume":"23","author":"W. Huang","year":"2023","unstructured":"Huang, W., Zhu, L., Huang, H., Li, Y., Wang, G., and Zhang, C. (2023) IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer, BMC Cancer, 23, 116, \nhttps:\/\/doi.org\/10.1186\/s12885-022-10353-5.","journal-title":"BMC Cancer"},{"key":"2864_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-024-01534-4","volume":"24","author":"D. Fu","year":"2024","unstructured":"Fu, D., Shi, X., Yi, X., Wu, D., He, H., Zhou, W., and Cheng, W. (2024) m6A reader IGF2BP2 promotes M2 macrophage polarization and malignant biological behavior of bladder cancer by stabilizing NRP1 mRNA expression, BMC Urol., 24, 147, \nhttps:\/\/doi.org\/10.1186\/s12894-024-01534-4.","journal-title":"BMC Urol."},{"key":"2864_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00545-1","volume":"29","author":"L. Lv","year":"2024","unstructured":"Lv, L., Wei, Q., Zhang, J., Dong, Y., Shan, Z., Chang, N., Zhao, Y., Bian, P., and Yi, Q. (2024) IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development, Cell. Mol. Biol. Lett., 29, 39, \nhttps:\/\/doi.org\/10.1186\/s11658-024-00545-1.","journal-title":"Cell. Mol. Biol. Lett."},{"key":"2864_CR48","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1093\/emboj\/cdf399","volume":"21","author":"F. M. Watt","year":"2002","unstructured":"Watt, F. M. (2002) Role of integrins in regulating epidermal adhesion, growth and differentiation, EMBO\u00a0J., 21, 3919-3926, \nhttps:\/\/doi.org\/10.1093\/emboj\/cdf399.","journal-title":"EMBO\u00a0J."},{"key":"2864_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"R. O. Hynes","year":"2002","unstructured":"Hynes, R. O. (2002) Integrins: bidirectional, allosteric signaling machines, Cell, 110, 673-687, \nhttps:\/\/doi.org\/10.1016\/S0092-8674(02)00971-6.","journal-title":"Cell"},{"key":"2864_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.humpath.2016.04.003","volume":"54","author":"R. L. Stewart","year":"2016","unstructured":"Stewart, R. L., West, D., Wang, C., Weiss, H. L., Gal, T., Durbin, E. B., O\u2019Connor, W., Chen, M., and O\u2019Connor, K. L. (2016) Elevated integrin \u03b16\u03b24 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer, Hum. Pathol., 54, 174-183, \nhttps:\/\/doi.org\/10.1016\/j.humpath.2016.04.003.","journal-title":"Hum. Pathol."},{"key":"2864_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejca.2016.03.072","volume":"60","author":"A. Ammothumkandy","year":"2016","unstructured":"Ammothumkandy, A., Maliekal, T. T., Bose, M. V., Rajkumar, T., Shirley, S., Thejaswini, B., Giri, V. G., and Krishna, S. (2016) CD66 and CD49f expressing cells are associated with distinct neoplastic phenotypes and progression in human cervical cancer, Eur.\u00a0J. Cancer, 60, 166-178, \nhttps:\/\/doi.org\/10.1016\/j.ejca.2016.03.072.","journal-title":"Eur.\u00a0J. Cancer"},{"key":"2864_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00585-y","volume":"7","author":"X. Duan","year":"2021","unstructured":"Duan, X., Li, H., Wang, M., Ju, S., Li, F., Chen, P., Lu, H., Han, X., and Ren, J. (2021) PSMC2\/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma, Cell Death Discov., 7, 217, \nhttps:\/\/doi.org\/10.1038\/s41420-021-00585-y.","journal-title":"Cell Death Discov."},{"key":"2864_CR53","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.3892\/ol.2019.10056","volume":"17","author":"L. Wei","year":"2019","unstructured":"Wei, L., Yin, F., Chen, C., and Li, L. (2019) Expression of integrin \u03b1-6 is associated with multi drug resistance and prognosis in ovarian cancer, Oncol. Lett., 17, 3974-3980, \nhttps:\/\/doi.org\/10.3892\/ol.2019.10056.","journal-title":"Oncol. Lett."},{"key":"2864_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030706","volume":"7","author":"N. Yamakawa","year":"2012","unstructured":"Yamakawa, N., Kaneda, K., Saito, Y., Ichihara, E., and Morishita, K. (2012) The increased expression of integrin \u03b16 (ITGA6) enhances drug resistance in EVI1(high) leukemia, PLoS One, 7, e30706, \nhttps:\/\/doi.org\/10.1371\/journal.pone.0030706.","journal-title":"PLoS One"},{"key":"2864_CR55","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ebiom.2019.07.068","volume":"47","author":"H. Jin","year":"2019","unstructured":"Jin, H., Ying, X., Que, B., Wang, X., Chao, Y., Zhang, H., Yuan, Z., Qi, D., Lin, S., Min, W., Yang, M., and Ji, W. (2019) N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer, EBioMedicine, 47, 195-207, \nhttps:\/\/doi.org\/10.1016\/j.ebiom.2019.07.068.","journal-title":"EBioMedicine"},{"key":"2864_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jare.2023.03.010","volume":"56","author":"X. Ying","year":"2024","unstructured":"Ying, X., Huang, Y., Liu, B., Hu, W. Y., Ji, D., Chen, C., Zhang, H., Liang, Y., Lv, Y., and Ji, W. (2024) Targeted m6A demethylation of ITGA6 mRNA by a multisite dCasRx-m6A editor inhibits bladder cancer development, J.\u00a0Adv. Res., 56, 57-68, \nhttps:\/\/doi.org\/10.1016\/j.jare.2023.03.010.","journal-title":"J.\u00a0Adv. Res."},{"key":"2864_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0741-1","volume":"18","author":"M. E. Law","year":"2016","unstructured":"Law, M. E., Ferreira, R. B., Davis, B. J., Higgins, P. J., Kim, J.-S., Castellano, R. K., Chen, S., Luesch, H., and Law, B. K. (2016) CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment, Breast Cancer Res., 18, 80, \nhttps:\/\/doi.org\/10.1186\/s13058-016-0741-1.","journal-title":"Breast Cancer Res."},{"key":"2864_CR58","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1038\/sj.onc.1204566","volume":"20","author":"M. Scherl-Mostageer","year":"2001","unstructured":"Scherl-Mostageer, M., Sommergruber, W., Abseher, R., Hauptmann, R., Ambros, P., and Schweifer, N. (2001) Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer, Oncogene, 20, 4402-4408, \nhttps:\/\/doi.org\/10.1038\/sj.onc.1204566.","journal-title":"Oncogene"},{"key":"2864_CR59","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.febslet.2007.02.025","volume":"581","author":"S. E. Perry","year":"2007","unstructured":"Perry, S. E., Robinson, P., Melcher, A., Quirke, P., B\u00fchring, H.-J., Cook, G. P., and Blair, G. E. (2007) Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells, FEBS Lett., 581, 1137-1142, \nhttps:\/\/doi.org\/10.1016\/j.febslet.2007.02.025.","journal-title":"FEBS Lett."},{"key":"2864_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1349-7006.2008.01066.x","volume":"100","author":"J. Ikeda","year":"2009","unstructured":"Ikeda, J., Oda, T., Inoue, M., Uekita, T., Sakai, R., Okumura, M., Aozasa, K., and Morii, E. (2009) Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung, Cancer Sci., 100, 429-433, \nhttps:\/\/doi.org\/10.1111\/j.1349-7006.2008.01066.x.","journal-title":"Cancer Sci."},{"key":"2864_CR61","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00432-008-0412-4","volume":"134","author":"Y. Awakura","year":"2008","unstructured":"Awakura, Y., Nakamura, E., Takahashi, T., Kotani, H., Mikami, Y., Kadowaki, T., Myoumoto, A., Akiyama, H., Ito, N., Kamoto, T., Manabe, T., Nobumasa, H., Tsujimoto, G., and Ogawa, O. (2008) Microarray-based identification of CUB-domain containing protein\u00a01 as a potential prognostic marker in conventional renal cell carcinoma, J.\u00a0Cancer Res. Clin. Oncol., 134, 1363-1369, \nhttps:\/\/doi.org\/10.1007\/s00432-008-0412-4.","journal-title":"J.\u00a0Cancer Res. Clin. Oncol."},{"key":"2864_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/onc.2012.547","volume":"33","author":"B. Casar","year":"2014","unstructured":"Casar, B., Rimann, I., Kato, H., Shattil, S. J., Quigley, J. P., and Deryugina, E. I. (2014) In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated \u03b21 integrin and induction of FAK\/PI3K\/Akt motility signaling, Oncogene, 33, 255-268, \nhttps:\/\/doi.org\/10.1038\/onc.2012.547.","journal-title":"Oncogene"},{"key":"2864_CR63","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1038\/s41388-019-0755-0","volume":"38","author":"F. Yang","year":"2019","unstructured":"Yang, F., Jin, H., Que, B., Chao, Y., Zhang, H., Ying, X., Zhou, Z., Yuan, Z., Su, J., Wu, B., Zhang, W., Qi, D., Chen, D., Min, W., Lin, S., and Ji, W. (2019) Dynamic m6A mRNA methylation reveals the role of METTL3-m6A-CDCP1 signaling axis in chemical carcinogenesis, Oncogene, 38, 4755-4772, \nhttps:\/\/doi.org\/10.1038\/s41388-019-0755-0.","journal-title":"Oncogene"},{"key":"2864_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01289-0","volume":"19","author":"X. Ying","year":"2020","unstructured":"Ying, X., Jiang, X., Zhang, H., Liu, B., Huang, Y., Zhu, X., Qi, D., Yuan, G., Luo, J., and Ji, W. (2020) Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development, Mol. Cancer, 19, 169, \nhttps:\/\/doi.org\/10.1186\/s12943-020-01289-0.","journal-title":"Mol. Cancer"},{"key":"2864_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1492648","volume":"15","author":"X. Chen","year":"2024","unstructured":"Chen, X., Xu, W., Pan, J., Yang, H., Li, Y., Chen, X., Sun, Y., Liu, Q., and Qiu, S. (2024) m6A methylation profiling as a prognostic marker in nasopharyngeal carcinoma: insights from MeRIP-Seq and RNA-Seq, Front. Immunol., 15, 1492648, \nhttps:\/\/doi.org\/10.3389\/fimmu.2024.1492648.","journal-title":"Front. Immunol."},{"key":"2864_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.717622","volume":"11","author":"A. Li","year":"2021","unstructured":"Li, A., Gan, Y., Cao, C., Ma, B., Zhang, Q., Zhang, Q., and Yao, L. (2021) Transcriptome-wide map of N6-methyladenosine methylome profiling in human bladder cancer, Front. Oncol., 11, 717622, \nhttps:\/\/doi.org\/10.3389\/fonc.2021.717622.","journal-title":"Front. Oncol."},{"key":"2864_CR67","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s11010-024-05040-x","volume":"479","author":"D.-H. Zhu","year":"2024","unstructured":"Zhu, D.-H., Su, K.-K., Ou-Yang, X.-X., Zhang, Y.-H., Yu, X.-P., Li, Z.-H., Ahmadi-Nishaboori, S.-S., and Li, L.-J. (2024) Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers, Mol. Cell. Biochem., 479, 1553-1570, \nhttps:\/\/doi.org\/10.1007\/s11010-024-05040-x.","journal-title":"Mol. Cell. Biochem."},{"key":"2864_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-021-03628-6","volume":"16","author":"S. Gavas","year":"2021","unstructured":"Gavas, S., Quazi, S., and Karpi\u0144ski, T. M. (2021) Nanoparticles for cancer therapy: current progress and challenges, Nanoscale Res. Lett., 16, 173, \nhttps:\/\/doi.org\/10.1186\/s11671-021-03628-6.","journal-title":"Nanoscale Res. Lett."},{"key":"2864_CR69","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1039\/D4NA00501E","volume":"6","author":"S. S. Palakurthi","year":"2024","unstructured":"Palakurthi, S. S., Shah, B., Kapre, S., Charbe, N., Immanuel, S., Pasham, S., Thalla, M., Jain, A., and Palakurthi, S. (2024) A comprehensive review of challenges and advances in exosome-based drug delivery systems, Nanoscale Adv., 6, 5803-5826, \nhttps:\/\/doi.org\/10.1039\/D4NA00501E.","journal-title":"Nanoscale Adv."},{"key":"2864_CR70","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s13346-023-01362-3","volume":"13","author":"D. M. Dogbey","year":"2023","unstructured":"Dogbey, D. M., Torres, V. E. S., Fajemisin, E., Mpondo, L., Ngwenya, T., Akinrinmade, O. A., Perriman, A. W., and Barth, S. (2023) Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy, Drug Deliv. Transl. Res., 13, 2719-2738, \nhttps:\/\/doi.org\/10.1007\/s13346-023-01362-3.","journal-title":"Drug Deliv. Transl. Res."},{"key":"2864_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1084-1","volume":"18","author":"C. Gu","year":"2019","unstructured":"Gu, C., Wang, Z., Zhou, N., Li, G., Kou, Y., Luo, Y., Wang, Y., Yang, J., and Tian, F. (2019) Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N(6)-methyladenosine of Notch1, Mol. Cancer, 18, 168, \nhttps:\/\/doi.org\/10.1186\/s12943-019-1084-1.","journal-title":"Mol. Cancer"},{"key":"2864_CR72","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3892\/ijmm.2020.4523","volume":"45","author":"L. Cao","year":"2020","unstructured":"Cao, L., Ren, Y., Guo, X., Wang, L., Zhang, Q., Li, X., Wu, X., Meng, Z., and Xu, K. (2020) Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2\/STAT3 pathway, Int. J. Mol. Med., 45, 1616-1626, \nhttps:\/\/doi.org\/10.3892\/ijmm.2020.4523.","journal-title":"Int. J. Mol. Med."},{"key":"2864_CR73","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.18632\/oncotarget.6681","volume":"7","author":"Y. Akiyama","year":"2016","unstructured":"Akiyama, Y., Koda, Y., Byeon, S.-J., Shimada, S., Nishikawaji, T., Sakamoto, A., Chen, Y., Kojima, K., Kawano, T., Eishi, Y., Deng, D., Kim, W. H., Zhu, W.-G., Yuasa, Y., and Tanaka, S. (2016) Reduced expression of SET7\/9, a histone mono-methyltransferase, is associated with gastric cancer progression, Oncotarget, 7, 3966-3983, \nhttps:\/\/doi.org\/10.18632\/oncotarget.6681.","journal-title":"Oncotarget"},{"key":"2864_CR74","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.3892\/or.2018.6621","volume":"40","author":"Y. Gu","year":"2018","unstructured":"Gu, Y., Wang, X., Liu, H., Li, G., Yu, W., and Ma, Q. (2018) SET7\/9 promotes hepatocellular carcinoma progression through regulation of E2F1, Oncol. Rep., 40, 1863-1874, \nhttps:\/\/doi.org\/10.3892\/or.2018.6621.","journal-title":"Oncol. Rep."},{"key":"2864_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061414","volume":"14","author":"F. L. Monteiro","year":"2022","unstructured":"Monteiro, F. L., Williams, C., and Helguero, L. A. (2022) A Systematic Review to Define the Multi-Faceted Role of Lysine Methyltransferase SETD7 in Cancer, Cancers (Basel)., 14, 1414, \nhttps:\/\/doi.org\/10.3390\/cancers14061414.","journal-title":"Cancers (Basel)."},{"key":"2864_CR76","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1080\/21691401.2019.1606006","volume":"47","author":"Y. Xie","year":"2019","unstructured":"Xie, Y., Zhao, J., Liang, Y., Chen, M., Luo, Y., Cui, X., Jiang, B., Peng, L., and Wang, X. (2019) MicroRNA-10b controls the metastasis and proliferation of colorectal cancer cells by regulating Kr\u00fcppel-like factor 4, Artif. Cells Nanomed., Biotechnol., 47, 1722-1729, \nhttps:\/\/doi.org\/10.1080\/21691401.2019.1606006.","journal-title":"Artif. Cells Nanomed., Biotechnol."},{"key":"2864_CR77","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41401-018-0050-6","volume":"40","author":"X.-T. Qi","year":"2019","unstructured":"Qi, X.-T., Li, Y.-L., Zhang, Y.-Q., Xu, T., Lu, B., Fang, L., Gao, J.-Q., Yu, L.-S., Zhu, D.-F., Yang, B., He, Q.-J., and Ying, M.-D. (2019) KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells, Acta Pharmacol. Sin., 40, 546-555, \nhttps:\/\/doi.org\/10.1038\/s41401-018-0050-6.","journal-title":"Acta Pharmacol. Sin."},{"key":"2864_CR78","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.juro.2013.08.087","volume":"191","author":"H. Li","year":"2014","unstructured":"Li, H., Wang, J., Xiao, W., Xia, D., Lang, B., Wang, T., Guo, X., Hu, Z., Ye, Z., and Xu, H. (2014) Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence, J.\u00a0Urol., 191, 493-501, \nhttps:\/\/doi.org\/10.1016\/j.juro.2013.08.087.","journal-title":"J.\u00a0Urol."},{"key":"2864_CR79","doi-asserted-by":"publisher","first-page":"102078","DOI":"10.18632\/oncotarget.22158","volume":"8","author":"X. Xu","year":"2017","unstructured":"Xu, X., Li, J., Zhu, Y., Xie, B., Wang, X., Wang, S., Xie, H., Yan, H., Ying, Y., Lin, Y., Liu, B., Wang, W., and Zheng, X. (2017) CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in\u00a0vitro and in\u00a0vivo, Oncotarget, 8, 102078-102087, \nhttps:\/\/doi.org\/10.18632\/oncotarget.22158.","journal-title":"Oncotarget"},{"key":"2864_CR80","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1111\/jcmm.15063","volume":"24","author":"H. Xie","year":"2020","unstructured":"Xie, H., Li, J., Ying, Y., Yan, H., Jin, K., Ma, X., He, L., Xu, X., Liu, B., Wang, X., Zheng, X., and Xie, L. (2020) METTL3\/YTHDF2 m6A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer, J.\u00a0Cell. Mol. Med., 24, 4092-4410, \nhttps:\/\/doi.org\/10.1111\/jcmm.15063.","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"2864_CR81","doi-asserted-by":"publisher","first-page":"633","DOI":"10.14670\/HH-18-671.","volume":"39","author":"J. Wang","year":"2024","unstructured":"Wang, J., Luo, J., Wu, X., and Li, Z. (2024) WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer, Histol. Histopathol., 39, 633-646, \nhttps:\/\/doi.org\/10.14670\/HH-18-671..","journal-title":"Histol. Histopathol."},{"key":"2864_CR82","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41556-020-0565-1","volume":"22","author":"M. Riegman","year":"2020","unstructured":"Riegman, M., Sagie, L., Galed, C., Levin, T., Steinberg, N., Dixon, S. J., Wiesner, U., Bradbury, M. S., Niethammer, P., Zaritsky, A., and Overholtzer, M. (2020) Ferroptosis occurs through an osmotic mechanism and propagates independently of cell rupture, Nat. Cell Biol., 22, 1042-1048, \nhttps:\/\/doi.org\/10.1038\/s41556-020-0565-1.","journal-title":"Nat. Cell Biol."},{"key":"2864_CR83","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11596-023-2814-6","volume":"44","author":"W. An","year":"2024","unstructured":"An, W., Gupta, R., Zhai, K., Wang, Y., Xu, W., and Cui, Y. (2024) Current and Potential Roles of Ferroptosis in Bladder Cancer, Curr. Med. Sci., 44, 51-63, \nhttps:\/\/doi.org\/10.1007\/s11596-023-2814-6.","journal-title":"Curr. Med. Sci."},{"key":"2864_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101107","volume":"23","author":"M. Dodson","year":"2019","unstructured":"Dodson, M., Castro-Portuguez, R., and Zhang, D. D. (2019) NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis, Redox Biol., 23, 101107, \nhttps:\/\/doi.org\/10.1016\/j.redox.2019.101107.","journal-title":"Redox Biol."},{"key":"2864_CR85","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P. Koppula","year":"2021","unstructured":"Koppula, P., Zhuang, L., and Gan, B. (2021) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy, Protein Cell, 12, 599-620, \nhttps:\/\/doi.org\/10.1007\/s13238-020-00789-5.","journal-title":"Protein Cell"},{"key":"2864_CR86","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2017.11.048","volume":"172","author":"I. Ingold","year":"2018","unstructured":"Ingold, I., Berndt, C., Schmitt, S., Doll, S., Poschmann, G., Buday, K., Roveri, A., Peng, X., Porto Freitas, F., Seibt, T., Mehr, L., Aichler, M., Walch, A., Lamp, D., Jastroch, M., Miyamoto, S., Wurst, W., Ursini, F., Arn\u00e9r, E. S. J., Fradejas-Villar, N., Schweizer, U., Zischka, H., Friedmann Angeli, J. P., and Conrad, M. (2018) Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis, Cell, 172, 409-422.e21, \nhttps:\/\/doi.org\/10.1016\/j.cell.2017.11.048.","journal-title":"Cell"},{"key":"2864_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05044-9","volume":"13","author":"I. de Souza","year":"2022","unstructured":"de Souza, I., Monteiro, L. K. S., Guedes, C. B., Silva, M. M., Andrade-Tomaz, M., Contieri, B., Latancia, M. T., Mendes, D., Porchia, B. F. M. M., Lazarini, M., Gomes, L. R., and Rocha, C. R. R. (2022) High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation, Cell Death Dis., 13, 591, \nhttps:\/\/doi.org\/10.1038\/s41419-022-05044-9.","journal-title":"Cell Death Dis."},{"key":"2864_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04927-1","volume":"13","author":"D. Wang","year":"2022","unstructured":"Wang, D., Tang, L., Zhang, Y., Ge, G., Jiang, X., Mo, Y., Wu, P., Deng, X., Li, L., Zuo, S., Yan, Q., Zhang, S., Wang, F., Shi, L., Li, X., Xiang, B., Zhou, M., Liao, Q., Guo, C., Zeng, Z., Xiong, W., and Gong, Z. (2022) Regulatory pathways and drugs associated with ferroptosis in tumors, Cell Death Dis., 13, 544, \nhttps:\/\/doi.org\/10.1038\/s41419-022-04927-1.","journal-title":"Cell Death Dis."},{"key":"2864_CR89","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.28251","volume":"63","author":"X. Sun","year":"2016","unstructured":"Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., and Tang, D. (2016) Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells, Hepatology, 63, 173-184, \nhttps:\/\/doi.org\/10.1002\/hep.28251.","journal-title":"Hepatology"},{"key":"2864_CR90","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/cas.14321","volume":"111","author":"T. Li","year":"2020","unstructured":"Li, T., Jiang, D., and Wu, K. (2020) p62 promotes bladder cancer cell growth by activating KEAP1\/NRF2-dependent antioxidative response, Cancer Sci., 111, 1156-1164, \nhttps:\/\/doi.org\/10.1111\/cas.14321.","journal-title":"Cancer Sci."},{"key":"2864_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01354-y","volume":"24","author":"J. Ma","year":"2024","unstructured":"Ma, J., Hu, J., Zhao, L., Wu, Z., Li, R., and Deng, W. (2024) Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment, BMC Urol., 24, 6, \nhttps:\/\/doi.org\/10.1186\/s12894-023-01354-y.","journal-title":"BMC Urol."},{"key":"2864_CR92","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10495-023-01817-5","volume":"28","author":"K. Wang","year":"2023","unstructured":"Wang, K., Wang, G., Li, G., Zhang, W., Wang, Y., Lin, X., Han, C., Chen, H., Shi, L., Reheman, A., Li, J., Li, Z., and Yang, X. (2023) m6A writer WTAP targets NRF2 to accelerate bladder cancer malignancy via m6A-dependent ferroptosis regulation, Apoptosis, 28, 627-638, \nhttps:\/\/doi.org\/10.1007\/s10495-023-01817-5.","journal-title":"Apoptosis"},{"key":"2864_CR93","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.3892\/ol.2018.9554","volume":"16","author":"L. Chen","year":"2018","unstructured":"Chen, L., and Wang, X. (2018) Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis, Oncol. Lett., 16, 6966-6970, \nhttps:\/\/doi.org\/10.3892\/ol.2018.9554.","journal-title":"Oncol. Lett."},{"key":"2864_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.598817","volume":"10","author":"N. Gao","year":"2020","unstructured":"Gao, N., Li, Y., Li, J., Gao, Z., Yang, Z., Li, Y., Liu, H., and Fan, T. (2020) Long non-coding RNAs: the regulatory mechanisms, research strategies, and future directions in cancers, Front. Oncol., 10, 598817, \nhttps:\/\/doi.org\/10.3389\/fonc.2020.598817.","journal-title":"Front. Oncol."},{"key":"2864_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00150","volume":"11","author":"T. Qin","year":"2020","unstructured":"Qin, T., Li, J., and Zhang, K.-Q. (2020) Structure, regulation, and function of linear and circular long non-coding RNAs, Front. Genet., 11, 150, \nhttps:\/\/doi.org\/10.3389\/fgene.2020.00150.","journal-title":"Front. Genet."},{"key":"2864_CR96","doi-asserted-by":"publisher","first-page":"13487","DOI":"10.1002\/jcb.28622","volume":"120","author":"H. Luo","year":"2019","unstructured":"Luo, H., Xu, C., Le, W., Ge, B., and Wang, T. (2019) lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150, J. Cell. Biochem., 120, 13487-13493, \nhttps:\/\/doi.org\/10.1002\/jcb.28622.","journal-title":"J. Cell. Biochem."},{"key":"2864_CR97","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2016.03.022","volume":"376","author":"Z. Zhang","year":"2016","unstructured":"Zhang, Z., Zhou, C., Chang, Y., Zhang, Z., Hu, Y., Zhang, F., Lu, Y., Zheng, L., Zhang, W., Li, X., and Li, X. (2016) Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT\/\u03b2-catenin pathway to promote growth and metastasis in colorectal cancer, Cancer Lett., 376, 62-73, \nhttps:\/\/doi.org\/10.1016\/j.canlet.2016.03.022.","journal-title":"Cancer Lett."},{"key":"2864_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28165","volume":"10","author":"Y. Huang","year":"2024","unstructured":"Huang, Y., Lv, Y., Yang, B., Zhang, S., Liu, B., Zhang, C., Hu, W., Jiang, L., Chen, C., Ji, D., Xiong, C., Liang, Y., Liu, M., Ying, X., and Ji, W. (2024) Enhancing m(6)A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer, Heliyon, 10, e28165, \nhttps:\/\/doi.org\/10.1016\/j.heliyon.2024.e28165.","journal-title":"Heliyon"},{"key":"2864_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J. Han","year":"2019","unstructured":"Han, J., Wang, J. Z., Yang, X., Yu, H., Zhou, R., Lu, H. C., Yuan, W. B., Lu, J. C., Zhou, Z. J., Lu, Q., Wei, J. F., and Yang, H. (2019) METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner, Mol. Cancer, 18, 110, \nhttps:\/\/doi.org\/10.1186\/s12943-019-1036-9.","journal-title":"Mol. Cancer"},{"key":"2864_CR100","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/s41388-023-02814-3","volume":"42","author":"J. Xie","year":"2023","unstructured":"Xie, J., Zhang, H., Wang, K., Ni, J., Ma, X., Khoury, C. J., Prifti, V., Hoard, B., Cerenzia, E. G., Yin, L., Zhang, H., Wang, R., Zhuo, D., Mao, W., and Peng, B. (2023) M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription, Oncogene, 42, 2956-2970, \nhttps:\/\/doi.org\/10.1038\/s41388-023-02814-3.","journal-title":"Oncogene"},{"key":"2864_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010114","volume":"12","author":"J. Liu","year":"2024","unstructured":"Liu, J., Tian, C., Qiao, J., Deng, K., Ye, X., and Xiong, L. (2024) m6A Methylation-Mediated Stabilization of LINC01106 Suppresses Bladder Cancer Progression by Regulating the miR-3148\/DAB1 Axis, Biomedicines, 12, 114, \nhttps:\/\/doi.org\/10.3390\/biomedicines12010114.","journal-title":"Biomedicines"},{"key":"2864_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216613","volume":"585","author":"J. Yi","year":"2024","unstructured":"Yi, J., Ma, X., Ying, Y., Liu, Z., Tang, Y., Shu, X., Sun, J., Wu, Y., Lu, D., Wang, X., Luo, J., Liu, B., Zheng, X., Lin, Y., Li, J., and Xie, L. (2024) N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128-3p\/MAPK1 axis, Cancer Lett., 585, 216613, \nhttps:\/\/doi.org\/10.1016\/j.canlet.2024.216613.","journal-title":"Cancer Lett."},{"key":"2864_CR103","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.7150\/thno.71456","volume":"12","author":"P. Liu","year":"2022","unstructured":"Liu, P., Fan, B., Othmane, B., Hu, J., Li, H., Cui, Y., Ou, Z., Chen, J., and Zu, X. (2022) M6A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism, Theranostics, 12, 6291-6307, \nhttps:\/\/doi.org\/10.7150\/thno.71456.","journal-title":"Theranostics"},{"key":"2864_CR104","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/1878-0261.13181","volume":"16","author":"C. Guimar\u00e3es-Teixeira","year":"2022","unstructured":"Guimar\u00e3es-Teixeira, C., Lobo, J., Miranda-Gon\u00e7alves, V., Barros-Silva, D., Martins-Lima, C., Monteiro-Reis, S., Sequeira, J. P., Carneiro, I., Correia, M. P., Henrique, R., and Jer\u00f3nimo, C. (2022) Downregulation of m6A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness, Mol. Oncol., 16, 1841-1856, \nhttps:\/\/doi.org\/10.1002\/1878-0261.13181.","journal-title":"Mol. Oncol."},{"key":"2864_CR105","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.canlet.2021.07.041","volume":"520","author":"N. Zhang","year":"2021","unstructured":"Zhang, N., Hua, X., Tu, H., Li, J., Zhang, Z., and Max, C. (2021) Isorhapontigenin (ISO) inhibits EMT through FOXO3A\/METTL14\/VIMENTIN pathway in bladder cancer cells, Cancer Lett., 520, 400-408, \nhttps:\/\/doi.org\/10.1016\/j.canlet.2021.07.041.","journal-title":"Cancer Lett."},{"key":"2864_CR106","doi-asserted-by":"publisher","first-page":"814","DOI":"10.5530\/ijper.58.3.89","volume":"58","author":"M. Xie","year":"2024","unstructured":"Xie, M., and Zhang, H. (2024) METTL14-mediate the biological effects of EMT in bladder Cancer cells by methylating SOX4 mRNA with m6A, Indian J. Pharm. Educ. Res., 58, 814-821, \nhttps:\/\/doi.org\/10.5530\/ijper.58.3.89.","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"2864_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215297","volume":"13","author":"E. Lavallee","year":"2021","unstructured":"Lavallee, E., Sfakianos, J. P., and Mulholland, D. J. (2021) Tumor heterogeneity and consequences for bladder cancer treatment, Cancers (Basel)., 13, 5297, \nhttps:\/\/doi.org\/10.3390\/cancers13215297.","journal-title":"Cancers (Basel)."},{"key":"2864_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14001","volume":"9","author":"C. Wang","year":"2023","unstructured":"Wang, C., Ma, D., Yu, H., Zhuo, Z., and Ye, Z. (2023) N6-methyladenosine (m6A) as a regulator of carcinogenesis and drug resistance by targeting epithelial-mesenchymal transition and cancer stem cells, Heliyon, 9, e14001, \nhttps:\/\/doi.org\/10.1016\/j.heliyon.2023.e14001.","journal-title":"Heliyon"},{"key":"2864_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00386-2","volume":"12","author":"W.-W. Liu","year":"2023","unstructured":"Liu, W.-W., Zhang, Z.-Y., Wang, F., and Wang, H. (2023) Emerging roles of m6A RNA modification in cancer therapeutic resistance, Exp. Hematol. Oncol., 12, 21, \nhttps:\/\/doi.org\/10.1186\/s40164-023-00386-2.","journal-title":"Exp. Hematol. Oncol."},{"key":"2864_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01680-z","volume":"21","author":"Z. Liu","year":"2022","unstructured":"Liu, Z., Zou, H., Dang, Q., Xu, H., Liu, L., Zhang, Y., Lv, J., Li, H., Zhou, Z., and Han, X. (2022) Biological and pharmacological roles of m(6)A modifications in cancer drug resistance, Mol. Cancer, 21, 220, \nhttps:\/\/doi.org\/10.1186\/s12943-022-01680-z.","journal-title":"Mol. Cancer"},{"key":"2864_CR111","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104514","volume":"39","author":"L. Wang","year":"2020","unstructured":"Wang, L., Hui, H., Agrawal, K., Kang, Y., Li, N., Tang, R., Yuan, J., and Rana, T. M. (2020) m(6) A RNA methyltransferases METTL3\/14 regulate immune responses to anti-PD-1 therapy, EMBO\u00a0J., 39, e104514, \nhttps:\/\/doi.org\/10.15252\/embj.2020104514.","journal-title":"EMBO\u00a0J."},{"key":"2864_CR112","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","volume":"82","author":"Z. Ni","year":"2022","unstructured":"Ni, Z., Sun, P., Zheng, J., Wu, M., Yang, C., Cheng, M., Yin, M., Cui, C., Wang, G., Yuan, L., Gao, Q., and Li, Y. (2022) JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA, Cancer Res., 82, 1789-1802, \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1323.","journal-title":"Cancer Res."},{"key":"2864_CR113","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omtn.2020.10.031","volume":"23","author":"H. Yu","year":"2021","unstructured":"Yu, H., Yang, X., Tang, J., Si, S., Zhou, Z., Lu, J., Han, J., Yuan, B., Wu, Q., Lu, Q., and Yang, H. (2021) ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2\u03b1-mediated glycolysis, Mol. Ther. Nucleic Acids, 23, 27-41, \nhttps:\/\/doi.org\/10.1016\/j.omtn.2020.10.031.","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2864_CR114","doi-asserted-by":"publisher","first-page":"87361","DOI":"10.18632\/oncotarget.13571","volume":"7","author":"X. Zhang","year":"2016","unstructured":"Zhang, X., Yang, X., Yang, C., Li, P., Yuan, W., Deng, X., Cheng, Y., Li, P., Yang, H., Tao, J., and Lu, Q. (2016) Targeting protein kinase CK2 suppresses bladder cancer cell survival via the glucose metabolic pathway, Oncotarget, 7, 87361-87372, \nhttps:\/\/doi.org\/10.18632\/oncotarget.13571.","journal-title":"Oncotarget"},{"key":"2864_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00543-3","volume":"29","author":"C. Xu","year":"2024","unstructured":"Xu, C., Zhou, J., Zhang, X., Kang, X., Liu, S., Song, M., Chang, C., Lin, Y., and Wang, Y. (2024) N(6)-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges, Cell. Mol. Biol. Lett., 29, 28, \nhttps:\/\/doi.org\/10.1186\/s11658-024-00543-3.","journal-title":"Cell. Mol. Biol. Lett."},{"key":"2864_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1937-y","volume":"10","author":"D. Priem","year":"2019","unstructured":"Priem, D., Devos, M., Druw\u00e9, S., Martens, A., Slowicka, K., Ting, A. T., Pasparakis, M., Declercq, W., Vandenabeele, P., van Loo, G., and Bertrand, M. J. M. (2019) A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanisms, Cell Death Dis., 10, 692, \nhttps:\/\/doi.org\/10.1038\/s41419-019-1937-y.","journal-title":"Cell Death Dis."},{"key":"2864_CR117","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-21-1518","volume":"81","author":"W. Wei","year":"2021","unstructured":"Wei, W., Sun, J., Zhang, H., Xiao, X., Huang, C., Wang, L., Zhong, H., Jiang, Y., Zhang, X., and Jiang, G. (2021) Circ0008399 Interaction with WTAP promotes assembly and activity of the m(6)A methyltransferase complex and promotes cisplatin resistance in bladder cancer, Cancer Res., 81, 6142-6156, \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1518.","journal-title":"Cancer Res."},{"key":"2864_CR118","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.7150\/ijbs.86719","volume":"20","author":"H. Yu","year":"2024","unstructured":"Yu, H., Zhuang, J., Zhou, Z., Song, Q., Lv, J., Yang, X., Yang, H., and Lu, Q. (2024) METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway, Int. J. Biol. Sci., 20, 1471-1491, \nhttps:\/\/doi.org\/10.7150\/ijbs.86719.","journal-title":"Int. J. Biol. Sci."},{"key":"2864_CR119","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cell.2012.05.003","volume":"149","author":"K. D. Meyer","year":"2012","unstructured":"Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., and Jaffrey, S. R. (2012) Comprehensive analysis of mRNA methylation reveals enrichment in 3\u2019 UTRs and near stop codons, Cell, 149, 1635-1646, \nhttps:\/\/doi.org\/10.1016\/j.cell.2012.05.003.","journal-title":"Cell"},{"key":"2864_CR120","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D. Dominissini","year":"2012","unstructured":"Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., Sorek, R., and Rechavi, G. (2012) Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq, Nature, 485, 201-206, \nhttps:\/\/doi.org\/10.1038\/nature11112.","journal-title":"Nature"},{"key":"2864_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84007-0","volume":"11","author":"M. Bayoumi","year":"2021","unstructured":"Bayoumi, M., and Munir, M. (2021) Evolutionary conservation of the DRACH signatures of potential N6-methyladenosine (m(6)A) sites among influenza A viruses, Sci. Rep., 11, 4548, \nhttps:\/\/doi.org\/10.1038\/s41598-021-84007-0.","journal-title":"Sci. Rep."},{"key":"2864_CR122","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/molbev\/msx320","volume":"35","author":"Z. Liu","year":"2018","unstructured":"Liu, Z., and Zhang, J. (2018) Most m6A RNA modifications in protein-coding regions are evolutionarily unconserved and likely nonfunctional, Mol. Biol. Evol., 35, 666-675, \nhttps:\/\/doi.org\/10.1093\/molbev\/msx320.","journal-title":"Mol. Biol. Evol."},{"key":"2864_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236882","volume":"15","author":"M. An","year":"2020","unstructured":"An, M., Wang, H., and Zhu, Y. (2020) Mutations in m6A consensus motifs are suppressed in the m6A modified genes in human cancer cells, PLoS One, 15, e0236882, \nhttps:\/\/doi.org\/10.1371\/journal.pone.0236882.","journal-title":"PLoS One"},{"key":"2864_CR124","doi-asserted-by":"publisher","first-page":"110635","DOI":"10.18632\/oncotarget.22372","volume":"8","author":"N. Deng","year":"2017","unstructured":"Deng, N., Zhou, H., Fan, H., and Yuan, Y. (2017) Single nucleotide polymorphisms and cancer susceptibility, Oncotarget, 8, 110635-110649, \nhttps:\/\/doi.org\/10.18632\/oncotarget.22372.","journal-title":"Oncotarget"},{"key":"2864_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02701-z","volume":"22","author":"J. Lv","year":"2022","unstructured":"Lv, J., Song, Q., Bai, K., Han, J., Yu, H., Li, K., Zhuang, J., Yang, X., Yang, H., and Lu, Q. (2022) N6-methyladenosine-related single-nucleotide polymorphism analyses identify oncogene RNFT2 in bladder cancer, Cancer Cell Int., 22, 301, \nhttps:\/\/doi.org\/10.1186\/s12935-022-02701-z.","journal-title":"Cancer Cell Int."},{"key":"2864_CR126","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.16.532618","volume":"10","author":"C. Zhang","year":"2023","unstructured":"Zhang, C., Tunes, L., Hsieh, M.-H., Wang, P., Kumar, A., Khadgi, B. B., Yang, Y., Doxtader, K. A., Herrell, E., Koczy, O., Setlem, R., Zhang, X., Evers, B., Wang, Y., Xing, C., Zhu, H., and Nam, Y. (2023) Cancer mutations rewire the RNA methylation specificity of METTL3-METTL14, bioRxiv Prepr. Serv. Biol., 10, eads4750, \nhttps:\/\/doi.org\/10.1101\/2023.03.16.532618.","journal-title":"bioRxiv Prepr. Serv. Biol."},{"key":"2864_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13050823","volume":"13","author":"F. Waldbillig","year":"2023","unstructured":"Waldbillig, F., Bormann, F., Neuberger, M., Ellinger, J., Erben, P., Kriegmair, M. C., Michel, M. S., Nuhn, P., and Nientiedt, M. (2023) An m6A-driven prognostic marker panel for renal cell carcinoma based on the first transcriptome-wide m6A-seq, Diagnostics, 13, 823, \nhttps:\/\/doi.org\/10.3390\/diagnostics13050823.","journal-title":"Diagnostics"},{"key":"2864_CR128","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.7150\/jca.99483","volume":"15","author":"G. Zhang","year":"2024","unstructured":"Zhang, G., Yang, J., Fang, J., Yu, R., Yin, Z., Chen, G., Tai, P., He, D., Cao, K., and Jiang, J. (2024) Development of an m6A subtype classifier to guide precision therapy for patients with bladder cancer, J.\u00a0Cancer, 15, 5204-5217, \nhttps:\/\/doi.org\/10.7150\/jca.99483.","journal-title":"J.\u00a0Cancer"}],"container-title":["Biochemistry (Moscow)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297924604441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S0006297924604441","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S0006297924604441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:23:05Z","timestamp":1773620585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S0006297924604441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2864"],"URL":"https:\/\/doi.org\/10.1134\/s0006297924604441","relation":{},"ISSN":["0006-2979","1608-3040"],"issn-type":[{"value":"0006-2979","type":"print"},{"value":"1608-3040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and consent to participate.\n                      This work does not contain any studies involving human and animal subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"Conflict of interest.\n                      The authors of this work declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}]}}